Modern
oncology
has
been
influenced
and
transformed
by
precision
personalized
medicine,
especially
with
the
introduction
of
therapy.
The
ever-increasing
knowledge
genome
contributes
to
advancement
medicine.
Liquid
biopsy
(LB)
is
a
diagnostic
approach
great
potential
for
use
in
LB
isolation
analysis
tumour-derived
components
such
as
circulating
tumour
cells,
DNA,
RNA
extracellular
vesicles.
continuous
development
new
techniques
field
holds
promise
its
widespread
use.
A
challenge
scientists
standardization
these
techniques,
allowing
their
application
clinical
practice.
This
review
presents
biological
characteristics
popular
methods
detection
analysis,
utility
biomarker
liquid
biopsy.
Journal of Extracellular Vesicles,
Journal Year:
2024,
Volume and Issue:
13(3)
Published: March 1, 2024
Abstract
Extracellular
vesicles
(EVs),
including
exosomes
and
microvesicles,
mediate
intercellular
communication
in
cancer,
from
development
to
metastasis.
EV‐based
liquid
biopsy
is
a
promising
strategy
for
cancer
diagnosis
as
EVs
can
be
found
patients’
body
fluids.
In
this
study,
the
lipid
composition
of
breast
cancer‐derived
was
studied
well
potential
blood
plasma
identification
biomarkers
detection.
Initially,
an
untargeted
lipidomic
analysis
carried
out
panel
cancerous
non‐cancerous
mammary
epithelial
cells
their
secreted
EVs.
We
that
are
enriched
sphingolipids
glycerophospholipids
compared
parental
cells.
The
initial
vitro
study
showed
correctly
classified
(100%
accuracy)
between
non‐cancerous,
into
respective
subtypes,
based
on
composition.
Subsequently,
women
diagnosed
with
(primary
or
progressive
metastatic
cancer)
healthy
women.
Correspondingly,
when
were
analysed,
patients
overall
accuracy
93.1%,
EVs’
Similarly,
primary
95%
correct
classification.
Furthermore,
cancers
89.5%.
This
reveals
lipids
may
source
detection
cancer.
Additionally,
demonstrates
usefulness
lipidomics
EV
EV‐associated
biomarker
discovery
studies.
proof‐of‐concept
starting
point
further
International Journal of Molecular Sciences,
Journal Year:
2024,
Volume and Issue:
25(16), P. 8594 - 8594
Published: Aug. 6, 2024
Liquid
biopsy,
a
noninvasive
diagnosis
that
examines
circulating
tumor
components
in
body
fluids,
is
increasingly
used
cancer
management.
An
overview
of
relevant
literature
emphasizes
the
current
state
liquid
biopsy
applications
care.
Biomarkers
particularly
DNA
(ctDNA),
RNAs
(ctRNA),
cells
(CTCs),
extracellular
vesicles
(EVs),
and
other
components,
offer
promising
opportunities
for
early
diagnosis,
treatment
selection,
monitoring,
disease
assessment.
The
implementation
precision
medicine
has
shown
significant
potential
various
types,
including
lung
cancer,
colorectal
breast
prostate
cancer.
Advances
genomic
molecular
technologies
such
as
next-generation
sequencing
(NGS)
digital
polymerase
chain
reaction
(dPCR)
have
expanded
utility
enabling
detection
somatic
variants
actionable
alterations
tumors.
also
demonstrated
predicting
responses,
monitoring
minimal
residual
(MRD),
assessing
heterogeneity.
Nevertheless,
standardizing
techniques,
interpreting
results,
integrating
them
into
clinical
routine
remain
challenges.
Despite
these
challenges,
implications
management,
offering
dynamic
approach
to
understanding
biology
guiding
personalized
strategies.
Cancers,
Journal Year:
2024,
Volume and Issue:
16(11), P. 1981 - 1981
Published: May 23, 2024
Effective
risk
assessment
in
early
breast
cancer
is
essential
for
informed
clinical
decision-making,
yet
consensus
on
defining
categories
remains
challenging.
This
paper
explores
evolving
approaches
stratification,
encompassing
histopathological,
immunohistochemical,
and
molecular
biomarkers
alongside
cutting-edge
artificial
intelligence
(AI)
techniques.
Leveraging
machine
learning,
deep
convolutional
neural
networks,
AI
reshaping
predictive
algorithms
recurrence
risk,
thereby
revolutionizing
diagnostic
accuracy
treatment
planning.
Beyond
detection,
applications
extend
to
histological
subtyping,
grading,
lymph
node
assessment,
feature
identification,
fostering
personalized
therapy
decisions.
With
rising
rates,
it
crucial
implement
accelerate
breakthroughs
practice,
benefiting
both
patients
healthcare
providers.
However,
important
recognize
that
while
offers
powerful
automation
analysis
tools,
lacks
the
nuanced
understanding,
context,
ethical
considerations
inherent
human
pathologists
patient
care.
Hence,
successful
integration
of
into
practice
demands
collaborative
efforts
between
medical
experts
computational
optimize
outcomes.
Discover Oncology,
Journal Year:
2025,
Volume and Issue:
16(1)
Published: March 24, 2025
The
use
of
Totally
Implantable
Venous
Access
Port
(TIVAP)
has
gained
importance
in
chemotherapy
for
cancer
patients
due
to
its
ability
reduce
complications
compared
conventional
central
venous
catheters.
Chemotherapy
breast
often
requires
long-term
access,
and
the
choice
device
can
impact
both
treatment
efficacy
patient
quality
life.
This
study
randomly
divided
355
patients,
who
were
treated
from
January
2022
2023,
into
TIVAP
group
(n
=
177)
control
178)
evaluate
application
effect
TIVAP.
used
totally
implantable
access
ports,
while
those
We
clinical
efficacy,
daily
life,
complications,
satisfaction
between
two
groups.
Statistical
analysis
was
performed
using
t-tests
continuous
data
χ2
tests
categorical
data.
Our
results
showed
that
total
96.61%
90.45%
group,
groups
significantly
different
(P
<
0.05).
Before
intervention,
living
scores
analyzed,
difference
not
significant
>
After
(77.41
±
7.02)
higher
than
(66.75
6.42)
0.05).In
terms
complication
rate,
5.08%,
which
lower
(12.36%),
Therefore,
effectively
toxic
side
effects
chemotherapy,
ensure
drugs
according
cycle,
then
improve
outcome.
Cytopathology,
Journal Year:
2025,
Volume and Issue:
unknown
Published: April 11, 2025
The
advent
of
personalised
and
precision
medicine
has
radically
modified
the
management
clinical
outcome
cancer
patients.
However,
expanding
number
predictive,
prognostic,
diagnostic
biomarkers
raised
need
for
simple,
noninvasive,
quicker,
but
equally
efficient
tests
molecular
profiling.
In
this
complex
scenario,
adoption
liquid
biopsy,
particularly
circulating
tumour
DNA
(ctDNA),
been
a
real
godsend
many
patients
who
would
otherwise
have
denied
benefits
targeted
treatments.
Undeniably,
ctDNA
analysis
several
advantages
over
conventional
tissue-based
analysis.
One
advantage
is
that
it
can
guide
treatment
decision
making,
especially
when
tissue
samples
are
scarce
or
totally
unavailable.
Indeed,
simple
blood
test
inform
clinicians
on
patients'
response
resistance
to
therapies,
help
them
monitor
minimal
residual
disease
(MRD)
after
surgical
resections,
facilitate
with
early
detection
interception.
Finally,
an
important
decipher
temporal
spatial
heterogeneity,
mechanism
highly
responsible
therapeutic
resistance.
review,
we
gathered
analysed
current
evidence
usefulness
in
solid
tumours.
Frontiers in Molecular Biosciences,
Journal Year:
2024,
Volume and Issue:
10
Published: Jan. 22, 2024
Background:
Cell-free
DNA
(cfDNA)
is
a
promising
biomarker
for
disease
prediction
in
many
cancers,
including
acute
leukemia
(acute
myeloid
[AML]
and
lymphoblastic
[ALL]).
This
study
investigated
the
role
of
cfDNA
predicting
relapse
or
unfavorable
outcomes
patients
upon
initial
diagnosis.
Methods:
Paired
peripheral
blood
samples
25
with
ALL
AML
were
compared
at
baseline
induction/follow-up
clinically
correlated
clinicopathological
outcome
variables
according
to
risk
category.
was
isolated
using
commercial
extraction
kits.
The
probability
poor
high-risk
groups
cut-off
value
stratification
minimal
residual
(MRD)
positivity
derived.
Results:
Twenty-five
diagnosed
risk-stratified
based
on
NCI
stratification,
these
patients,
4
standard
(SR)
1
patient
intermediate
(IR),
while
majority
(80%)
high
(HR).
Of
these,
four
HR
passed
away.
ratio
reduction
end
induction
strong
predictor
regardless
MRD
status.
A
score
2.6
higher
diagnosis/remission
predicted
outcomes,
accuracy
than
conventional
detection
by
flow
cytometry.
Conclusion:
predicts
patients.
pilot
suggests
that
scoring
may
be
useful
tool
prognosis
